Serum levels of IGF-I and IGFBP-III and their relation with carcinoembryonic antigen and carbohydrate antigen 19-9 in cases of esophageal cancer

International Journal of Clinical Practice

Volumn 60, Issue 12, 2006, Pages 1604-1608

  Yilmaz, O ^a   Eroglu, Atilla ^a   Dag, E ^a   Karaoglanoglu, N ^a   Yilmaz, A ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

CA19 9; CEA; IGF I; IGFBP III; Oesophageal cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESOPHAGEAL NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 33751000730     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00854.x     Document Type: Article

References (22)

1. Kadayifci A, Benekli M, Savas C. Tümör belirleyicileri. Türkiye Týp Dergisi 1994; 1: 273-84.
2. Reubi JC. The role of peptides and their reseptors as tumor markers. Endocrinol Metab Clin North Am 1993; 22: 917-39.
3. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effect of IGF's on tumorigenesis and neoplastic growth. Endocrine Rev 1994; 21: 215-44.
4. Jerome L, Shiryand L, Leyland-Jones B. Deregulation of the IGF axis in cancer: Epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-78.
5. Liu YC, Leu CM, Wong FH. Autocrine stimulation by insulin-like growth factor IIs involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002; 9: 665-74.
6. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-20.
7. Rogler CE, Yang D, Rossetti L et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779-84.
8. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor-II (IGF-II). Br J Cancer 1995; 72: 1189-93.
9. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-9.
10. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype. Cancer Res 1999; 59: 3588-91.
11. Yee D, Favoni RE, Lippman ME, Powell DR. Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 1991; 18: 3-10.
12. Reeve JG, Morgan J, Schwander J, Bleehen NM. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 1993; 53: 4680-5.
13. Chen JC, Shao ZM, Sheikh MS et al. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I) -mediated DNA synthesis and IGF-I binding in a human breast cancer carcinoma cell line. J Cell Physiol 1994; 158: 69-78.
14. Camacho-Hubner C, McCusker RH, Clemmons DR. Secretion and biological actions of insulin-like growth factor binding proteins in two human tumor-derived cell lines in vitro. J Cell Physiol 1991; 148: 281-9.
15. Liu YC, Leu CM, Wong FH, Fong WS. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002; 9: 665-74.
16. Siewert JR, Roder JD. Lymphadenectomy in esophageal cancer surgery. Dis Esophagus 1992; 5: 91-7.
17. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993; 53: 1102-6.
18. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 1992; 52: 6447-51.
19. Baserga R. The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 1995; 55: 249-52.
20. Chen SC, Chou CK, Wong FH. Overexpression of epidermal growth factor and insulin-like factor I receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res 1991; 51: 1898-903.
21. Mealy K, Feely J, Reid I, McSweeney J et al. Tumor marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996; 22: 505-7.
22. Ikeda Y, Kuwano H, Ikebe M et al. Immunohistochemical detection of CEA, CA19-9 and DF3 in esophageal carcinoma limited to the submucosal layer. J Surg Oncol 1994; 56: 7-12.